

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person* <u>Trowbridge Stephen A</u> <hr/> (Last) (First) (Middle) <u>14 PLAZA DRIVE</u> <hr/> (Street) <u>LATHAM NY 12110</u> <hr/> (City) (State) (Zip)			2. Issuer Name and Ticker or Trading Symbol <u>ANGIODYNAMICS INC [ANGO]</u>			5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director _____ 10% Owner _____ Officer (give title below) <input checked="" type="checkbox"/> Other (specify below) <u>EVP and CFO</u>		
			3. Date of Earliest Transaction (Month/Day/Year) <u>08/12/2021</u>			6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person		
			4. If Amendment, Date of Original Filed (Month/Day/Year) <u>08/17/2021</u>					

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock ⁽¹⁾	08/12/2021		M		10,946 ⁽²⁾	A	\$0	79,254	D	
Common Stock ⁽¹⁾	08/12/2021		F		4,173 ⁽³⁾	D	\$27.29	75,081	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Performance Right	(4)	08/12/2021		M			9,437	(4)	(4)	Common Stock	9,437	\$0.00	0.00	D	

Explanation of Responses:

- On August 17, 2021, the reporting person filed a Form 4 to report the vesting and settlement of performance share units and the sale of certain underlying shares of common stock ("Common Stock") of AngioDynamics, Inc. (the "Company"), which contained administrative errors as to the terms of the performance share units and the number of shares of Common Stock of the Company issued and sold.
- This acquisition of 10,946 shares of Common Stock of the Company represents shares acquired through the vesting and settlement of performance share units granted to the reporting person on July 18, 2018.
- The exempt disposition of 4,173 shares of Common Stock of the Company was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying performance share units granted to the reporting person on July 18, 2018.
- On July 18, 2018, the reporting person received a target grant of 9,437 performance share units. Between 0% and 200% of the target number was to be earned based on total shareholder return relative to a peer group of companies over a three-year performance period ending May 31, 2021. Based on performance over the period, 10,946 shares of Common Stock were issued to the reporting person under this grant.

/s/ Richard C. Rosenzweig,
Attorney in Fact

08/17/2021

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.